Biocept Q3 Revenues Drop 31 Percent as Test Volume Shrinks

Nov 13, 2018

|

This story has been updated to include comments from Biocept's earnings call with analysts.

NEW YORK (GenomeWeb) – Biocept reported after the close of the market Tuesday that its third quarter 2018 revenues plunged 31 percent year over year as total test volumes shrank 28 percent.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

Biocept Q3 Revenues Drop 31 Percent as Test Volume Shrinks

To read the full story....

Breaking News

Mount Sinai Coronavirus Antibody Test Gets NYSDOH Emergency Use Authorization for Quantitative Use

In Brief This Week: Illumina, Siemens Healthineers, Danaher, Abbott, and More

Qiagen Acquires Remaining Stake in NeuMoDx Molecular for $248M

New York City Opening Dedicated COVID-19 Testing Laboratory

Scipher Medicine Taps Ambry Genetics to Scale Up TNF Inhibitor Response Test

FDA Proposes Reclassification of Cytomegalovirus Quantitative Tests

What's Popular?

Roche Gets FDA Emergency Use Authorization for Rapid Coronavirus, Flu Test

Cellex, Gauss Partner on At-Home, Point-of-Care Coronavirus Antigen Test

Novacyt H1 Revenues Surge on Coronavirus Testing Product Sales

Cytek Biosciences Gets CE Mark for Flow Cytometer

Baxter to Exclusively Distribute BioMérieux Acute Kidney Injury Dx Test in Europe, US

Sponsorships